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Photodynamic therapy (PDT) is a method of destroying cancer by
free radical oxidation necrosis. This is achieved by photo-
activating a dye (the photosensitizing agent) in cancer tissue. This
process generates oxygen species, which destroy the cell
organelles. It is an aim of PDT to destroy superficially localized
tumours selectively while sparing surrounding tumour-free struc-
tures. However, it is well-recognized that PDT is not yet optimized
in this respect. For example, several reports have documented
PDT-related injuries on normal tissues in clinical (Pass et al, 1994;
Takita et al, 1994) and experimental (Pelton et al, 1992; Ris et al,
1993a, 1993b; Stewart et al, 1993; Ji et al, 1994; Tochner et al,
1994; Veenhuizen et al, 1994) settings. Thus, there have been
many efforts to improve selective action; for example, by devel-
oping new photosensitizers, modulating drug-light conditions, and
improving light dosimetry (Ash and Brown 1993; Levy 1994). For
example, m-tetrahydroxyphenylchlorin (mTHPC), a chlorin class
sensitizer, has shown better therapeutic gains and a more rapid
reduction of skin photosensitization than Photofrin in comparative
studies in mice (van Geel et al, 1995). It has been shown in a
rodent model to accumulate in high concentrations in tumours and
the reticuloendothelial system but not in muscular organs such as
the heart (Alian et al, 1994). In common with hematoporphyrin
derivatives (HpD), PDT with mTHPC seems to act at least partly
via a type II process where singlet oxygen is generated (Ma et al,
1994). The quantum yield for photoinactivation of cells is smaller
for mTHPC than for other sensitizers (Ma et al, 1994).
We have assessed intraoperative intracavitary PDT of the chest
using mTHPC in patients suffering from malignant pleural
mesothelioma; 0.3mg/kg body weight mTHPC were injected i.v.
and laser light (10J/cm2) at 652nm was delivered at a drug-light
interval of 2 days. This resulted in tumour necrosis up to 10mm
deep (Ris et al, 1991), and suggested that mTHPC is an efficient
second-generation sensitizer for clinical application. Similar find-
ings emerged from experimental settings of other investigators
(Lofgren et al, 1994; Ma et al, 1994; van Geel et al, 1995) However,
as serious PDT-related side-effects were observed in our patients,
we orientated our research towards optimization of mTHPC—PDT
by changing drug-light conditions in an experimental setting with
nude mice bearing human malignant mesothelioma xenografts. The
tumour and tumour-free tissue that served as control were treated
under the same conditions and the extent of PDT-related tumour
necrosis and normal tissue injury were compared in order to assess
the therapeutic ratio for each drug-light parameter. We observed
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Inselspital, CH-3010 Bern, Switzerlandthat the therapeutic ratio of mTHPC—PDT was highly dependent on
the drug-light interval, and that best results were obtained at an
interval of 3 days (Ris et al, 1993a). Selectivity was further
enhanced in the model by decreasing the drug dose to 0.1 mg/kg
body weight while increasing the light dose to 20 J/cm2, 0.2 W/cm2
at drug-light intervals ranging from 2 to 4 days (Ris et al, 1993b).
We are now exploring the effect of structural modification of the
sensitizer itself to see if photosensitizing effects and therapeutic
ratios can be improved still further. The photosensitizing effects of
mTHPC and polyethylene glycol-derived mTHPC (pegylated
mTHPC) were compared with respect to their photosensitizing
properties in nude mice bearing different human tumour
xenografts.
MATERIALS AND METHODS
Tumours and animals
Human malignant mesothelioma (Reale et al, 1987), poorly differ-
entiated human squamous cell carcinoma of the oral cavity
(Altermatt et al, 1988) and poorly differentiated human adeno-
carcinoma of the colon (Altermatt et al, 1988) were xenografted on
BALB/c nude mice using the trocar technique. At least 6 passages
on nude mice were performed for each tumour type after thawing
from liquid nitrogen before treatment was initiated. The tumour
volume doubling time was 300 h for mesothelioma, 113 h for
squamous cell carcinoma and 135 h for adenocarcinoma xeno-
grafts. One tumour was grown subcutaneously on the right flank
of each animal and treatment was initiated when the tumour
reached a diameter of 10—12 mm. Animal housing included artifi-
cial light in a 12 h rhythm before and after administration of the
photosensitizer.
Drug administration
m-THPC (Bonnett et al, 1989) from Scotia (Guildford, UK) was
dissolved in a pharmaceutical-grade solution of 20% ethanol, 30%
polyethylene glycol 400 and 50% H2O for administration.
Pegylated mTHPC from Scotia is a water-soluble high molecular-
weight derivative of mTHPC, prepared by covalently binding
polyethylene glycol 5000, to each of the four hydroxy residuals to
give tetrakis (methoxy PEG 5000) ether of 7,8-dihydro-
5,10,15,20-tetrakis-(3-hydroxyphenyl)-21,23-(H)-porphyrin. Its
molecular weight is approximately 20 000. It was dissolved in
sterile 0.9% NaCl for administration.
mTHPC (0.1 mg/kg) and an equimolar dose of pegylated
mTHPC was injected i.p. into 90 mice (45 animals for each
compound), meaning that the same amount of mTHPC (the active
moiety) was always compared irrespective of the molecular
weight of the sensitizer.
Light delivery
Before light delivery, the animals were anaesthetized with Avertin
i.p. (Sterling Winthrop, NY, USA) and kept on a warm towel pad
during treatment. Argon-pumped dye laser light of 652 nm was
delivered through a quartz optical fibre containing a lens. A power
track system allowed for a constant power output (Coherent
Innova 200 and Dye CR 599, GMP SA, Lausanne, Switzerland).
In each animal, non-contact surface irradiation was performed on
the tumour (through the intact skin overlying the tumour) and on
an equal-sized area of the hind leg serving as control site for
normal tissue. The irradiated spots were 1.3 cm in diameter and
the treated surfaces were situated perpendicular to the incident
laser beam. The power at the end of the fibre was measured by a
power meter calibrated for 652 nm, allowing for non-thermal
power density on the irradiated surfaces of 0.2 W/cm2. A dose of
20 J/cm2 was delivered on each spot, the treatment time (100 s)
was controlled by a time shutter.
Groups of 6 animals were assessed for each drug-light condition
and each compound: mesothelioma xenografts were treated at
drug-light intervals of 1, 2, 3 and 4 days (8 groups), squamous cell
carcinoma xenografts at a drug-light interval of 4 days (2 groups)
and adenocarcinoma xenografts at a drug-light interval of 4 days
(2 groups).
Assessment of tumour and normal tissue injury
Seventy-two hours after light delivery the animals were eutha-
nized by ether overdose. The whole animals were fixed in neutral
buffered formalin (10%). The tumours and control sites were cut at
a right angle to the surface from the centre to the periphery,
routinely processed and paraffin embedded. The extent of necrosis
in the irradiated tumours was expressed as an area (measured by
planimetry) rather than depth as this is more accurate for inhomo-
geneous necrosis seen in a nodular tumour (Ris et al, 1993b). A
transparent grid with 1 mm spacing was placed over the histolog-
ical section taken through the largest diameter of the tumour and
the number of grid intersections falling within the necrotic or non-
necrotic tumour area were counted with the aid of a dissecting
microscope (magnification ´ 16). This procedure was repeated
three times at different angles and the median value was used for
statistical analysis. Since this approach could not be applied to
the layered structures of normal tissue from the control site
comprising skin and muscle, the maximum depth of visible change
(necrosis, leucocytic infiltration, oedema and depletion of hair
follicles) was measured in the control site as described earlier (Ris
et al, 1993a). Tumour and normal tissue damage was histologi-
cally assessed by an independent pathologist (HJA) without
knowledge of the treatment performed.
Sensitizer tissue concentration measurements
Sensitized but non-irradiated animals were asphyxiated in ether
4 days after i.p. administration of 0.1 mg/kg mTHPC and an
equimolar dose of pegylated mTHPC, respectively. Three animals
were assessed for each type of tumour and each compound. The
tumours, free of overlying tissue with a size of 10—12 mm in diam-
eter, were dissected and muscle and skin of the hind leg as well as
lung, heart, liver, kidney, spleen and gut were harvested. The spec-
imens were irrigated in 0.9% NaCl, frozen in liquid nitrogen and
stored at —70°C. The tissue concentrations of the two compounds
were measured by high-performance liquid chromatography
(HPLC) as follows.
mTHPC
The tissues (100—200 mg) were homogenized in 2 ml of the
homogenizing medium (8 parts methanol—DMSO 4:1 v/v
containing the internal standard paratetrahydroxyphenylchlorin
and 1 part water) in a Dounce homogenizer. The mixture was
transferred into a clean tube and centrifuged at 2600 g for 10 min.
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of water, and 200 ml of the solution was injected. The column
consisted of hypersil—ODS (5 mm) and the mobile phase of
acetonitrile-0.1% TFA (77:23 v/v). The flow rate was 1 ml/min. A
linear UVIS-204 detector set at 416 nm and a Perkin-Elmer
(Norwalk, CT, USA) LS-3 fluorometer set at 406 nm (excitation)
and 653 nm (emission) were used.
Pegylated mTHPC
This was analysed as mTHPC following acid hydrolysis as follows.
The tissues were homogenized with 25% HCl—DMSO (9:1 v/v)
using 0.5 ml of homogenizing solution per 100 mg tissue. The
homogenate was transferred to a 5 ml glass tube, flushed with N2
and heated for 1 h at 70°C. After cooling to room temperature the
homogenate was centrifuged at 4000 g for 15 min. The supernatant
was withdrawn and the residue extracted by vortex-mixed with 0.5
ml of MeOH/DMSO (4:1 v/v) and centrifuged at 4000 RPM for 15
min. Four hundred microlitres of the supernatant was withdrawn and
the residue was mixed with 200 ml of water and again centrifuged at
8800 g for 5 min. Two hundred microlitres of the supernatant was
then injected into the HPLC column.
Controls
The histological pattern of the tumour was assessed on 6 non-
sensitized, non-irradiated animals for each type of xenograft to
determine the vascular architecture and the extent of spontaneous
tumour necrosis.
Statistical analysis
The Student￿s t-test for paired and unpaired observations was
applied where appropriate by using a two-tailed hypothesis.
Significance was accepted at P < 0.05.
RESULTS
Photosensitizing effects on tumour free tissue (Table 1)
At an interval of 1 day, substantial necrosis comprising skin and
underlying muscle was observed with mTHPC as sensitizer at
0.1 mg/kg and a light dose of 20 J/cm2. At drug-light intervals
ranging from 2 to 4 days, mTHPC led to negligible changes (scat-
tered leucocytes) in normal tissues using the same drug-light
condition. Photoactivation with the same light conditions and an
equimolar dose of pegylated mTHPC did not cause histologically
recognizable changes in normal tissue at any drug-light interval
assessed (Figure 1).
Photosensitizing effects on malignant xenografts
Controls
Adenocarcinoma xenografts revealed histologically a delicate
tumour stroma with numerous small capillary vessels. In contrast,
malignant mesothelioma and squamous cell carcinoma were poor
in stroma and blood vessels. The extent of spontaneous tumour
necrosis was not significantly different for the three neoplasms. It
was focal-diffuse in all three types of xenografts and revealed a
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Table 1 Extent of photosensitized tumour necrosis and normal tissue alterations for mTHPCa and pegylated mTHPCb on
mesothelioma xenografts
Tumour-free tissue (mm ± 1 SD) Tumour (mm2 ± 1 SD)
Drug-light mTHPC Pegylated mTHPC Pegylated
interval (days) mTHPC mTHPC
1 2.6 ± 0.6 0 43.4 ± 32.8 37.2 ± 33.1
2 0.1 0 38.5 ± 28.2 55.9 ± 32.2
3 0.1 0 36.9 ± 16.6 53.4 ± 9.6
4 0.1 0 39.3 ± 27.3 86.3 ± 25.1
a0.1 mg/kg mTHPC, light dose 20 J/cm2. bThe dose of pegylated mTHPC was equimolar to 0.1 mg/kg mTHPC; light dose 20 J/cm2.
AB
Figure 1 Histological assessment of skin and underlying muscle of the hind leg of untreated animals (A), and after PDT with pegylated mTHPC equimolar
dosed to 0.1 mg/kg mTHPC, 20 J/cm2 and a drug-light interval of 1 day without obvious alterations except depletion of hair follicles assessment 72 h after
irradiation (haematoxylin & eosin, bar = 0.2 mm), (B)histomorphological pattern which was distinct from that observed
72 h after PDT (Figure 2).
Mesothelioma xenografts (Table 1)
mTHPC (0.1 mg/kg) and 20 J/cm2 resulted in substantial PDT-
induced tumour necrosis at drug-light intervals ranging from 1 to 4
days, without significant differences between these time points.
Pegylated mTHPC equimolar dosed to mTHPC and 20 J/cm2
resulted in a significant increase of tumour necrosis compared to
that of mTHPC at drug-light intervals of 3 days (P < 0.05) and 4
days (P < 0.005). At drug-light intervals of 1 and 2 days, there was
no significant difference in tumour necrosis between the two
sensitizers. Comparing the pegylated mTHPC-induced tumour
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A
B
C
Figure 2 Histological assessment of xenografts of non-sensitized, non-
irradiated animals: malignant mesothelioma (A), squamous cell carcinoma
(B) and adenocarcinoma (C), revealing typical small focal-diffuse areas of
spontaneous necrosis (arrows) within otherwise viable tumour (haematoxylin
& eosin, bar = 0.2 mm)
Table 2 Extent of photosensitized tumour necrosis for mTHPCa and
pegylated mTHPCb in human mesothelioma, squamous cell carcinoma and
adenocarcinoma xenografts (mm2 ± 1 SD)
Mesothelioma Squamous cell Adeno-
carcinoma carcinoma
Control 5.0 ± 7.2 6.5 ± 4.7 11.5 ± 7.6
mTHPC 39.3 ± 27.3 19.5 ± 3.8 83.1 ± 37.8
Pegylated
mTHPC 86.3 ± 25.1 58.4 ± 23.3 81.5 ± 23.4
a0.1 mg/kg mTHPC, light dose 20 J/cm2, drug-light interval 4 days. bThe dose
of pegylated mTHPC was equimolar to 0.1 mg/kg mTHPC; light dose
20 J/cm2, drug-light interval 4 days.
A
B
C
Figure 3 Histological assessment of xenografts after PDT with pegylated
mTHPC equimolar dosed to 0.1 mg/kg mTHPC, 20 J/cm2 and a drug-light
interval of 4 days: malignant mesothelioma (A), squamous cell carcinoma (B)
and adenocarcinoma (C), with extensive photosensitized necrosis.
Assessment 72 h after irradiation (haematoxylin & eosin, bar = 0.2 mm)necrosis at different time points, it was significantly larger at a
drug-light interval of 4 days than at 1 day (P < 0.02), 2 days
(P < 0.05) and 3 days (P < 0.01).
Comparison between mesothelioma, squamous cell
carcinoma and adenocarcinoma xenografts (Table 2)
mTHPC (0.1 mg/kg) and 20 J/cm2 at a drug-light interval of 4 days
resulted in larger tumour necrosis than observed in controls for
all tumour types (P < 0.005). Adenocarcinoma displayed larger
necrosis than squamous cell carcinoma (P < 0.001) and malignant
mesothelioma (P < 0.02), whereas no significant difference
between squamous cell carcinoma and malignant mesothelioma
was observed. Pegylated mTHPC equimolar dosed to mTHPC and
20 J/cm2 at a drug-light interval of 4 days resulted in extensive
tumour necrosis for all xenografts without significant difference
between malignant mesothelioma, squamous cell carcinoma and
adenocarcinoma. The extent of necrosis was significantly larger
with pegylated mTHPC than with mTHPC with this drug-light
condition for malignant mesothelioma (P < 0.01) and squamous
cell carcinoma (P < 0.001), but not for adenocarcinoma (Figure 3).
Tissue concentration measurements (Table 3)
There was no significant difference in the tumour tissue concentra-
tion between mTHPC and pegylated mTHPC in adenocarcinoma,
mesothelioma and squamous cell carcinoma xenografts 4 days
after administration of the sensitizers. No difference was found in
mTHPC uptake between the three types of tumour. Pegylated
mTHPC revealed a lower uptake in squamous cell carcinoma than
in adenocarcinoma xenografts (P < 0.05).
Four days after administration, significantly higher tissue
concentrations were measured for pegylated mTHPC than
mTHPC in heart (P < 0.001), lung (P < 0.01), spleen (P < 0.001),
and liver (P < 0.001), and a lower concentration in kidney
(P < 0.01). No significant difference was found between the two
sensitizers in this respect in gut, skin and muscle tissue.
DISCUSSION
The ability of mTHPC to produce tumour necrosis even with small
light doses under clinical (Ris et al, 1991) and experimental condi-
tions (Lofgren et al, 1994), makes this compound attractive for its
use in intraoperative PDT, given the short treatment time required.
However, injuries to normal tissues have been observed in experi-
mental settings after PDT with mTHPC, especially if high drug or
light doses were applied at a short drug-light interval (Ris et al,
1993a, 1993b; Veenhuizen et al, 1994; van Geel et al, 1995). Even
low doses of sensitizer (0.2 mg/kg) and light (8—12 J/cm2) have
resulted in severe normal tissue damage of rats after whole
abdomen i.p. PDT (Veenhuizen et al, 1994), emphasizing the need
for optimization of mTHPC before its routine clinical use in intra-
abdominal, or intrathoracic adjunctive therapy. This study was
undertaken to improve the efficacy and tumour selectivity of PDT,
and compared mTHPC with pegylated mTHPC on different
tumour xenografts in order to establish experimental fundamentals
before clinical application.
Polyethylene glycol is a long-chain water-soluble polyether that
is widely used as a pharmaceutical vehicle. Recently it has been
found that covalent binding of polyethylene glycol to pharmaceu-
ticals (pegylation) confers benefits beyond that where it is used
as a vehicle alone (Burnham, 1994). These include decreased
immunogenicity and absorption by the liver, increased drug circu-
lation time and enhanced tumour uptake for anticancer drugs. So
far pegylation has mainly been applied to high molecular-weight
substances such as proteins, enzymes and liposomes, but the
pharmaceutical benefits may possibly be conferred upon other
compounds. Other studies have shown that the uptake of pegylated
phthalocyanine sensitizers in animal tumours is enhanced with
increased tumour-to-skin uptake ratios compared to the non-
pegylated compound (All￿mann et al, 1995).
Pegylated mTHPC is mTHPC covalently bound to polyethylene
glycol 5000 at each of the four hydroxy groups. It is water-soluble
and has an average molecular weight of 20 000. Our results
suggested an enhanced uptake of pegylated mTHPC in meso-
thelioma and adenocarcinoma compared to mTHPC 4 days after
injection, but these differences were not significant. Pegylated
mTHPC gave rise to better tumour-to-skin and tumour-to-muscle
uptake ratios than mTHPC in mesothelioma and adenocarcinoma
but not in squamous cell carcinoma xenografts. In contrast,
pegylated mTHPC revealed significantly higher concentrations
compared to mTHPC in liver, spleen, heart and lung tissue at this
time point. Our results suggest a difference in biodistribution of
the two substances similar to that observed with pegylated and
non-pegylated phthalocyanines (All￿mann et al, 1995).
The effect of PDT depends on a complex matrix of conditions
such as tissue concentration and localization of the photosensitizer,
oxygenation of the tumours, optical properties of the target tissue
and on activation wavelength, power density and other treatment
conditions. An intact blood supply is needed to ensure oxygenation
of target tissues. Therefore, in vivo (rather than ￿in vitro￿) investi-
gations are essential to assess efficacy and tissue selectivity of PDT.
A simple and reproducible animal model has to be chosen due to
the large number of variables to be tested. Rodents bearing subcuta-
neously implanted tumours are an appropriate model for comparing
circulation since tumours grow well and are easily accessible to
PDT. However, xenografts do not reflect the natural growth pattern
of the tumours or the environment where they arise in humans. We
have chosen nude mice bearing human tumour xenografts since
these tumours preserve features of the original tumour (Houghton
and Houghton, 1987). The extent of injury in the tumour and
tumour-free tissues on the same animal treated under the same
drug-light conditions is the most direct way to assess the efficacy
and tumour selectivity of PDT (Berenbaum et al, 1982). Our
Comparison of photodynamic effects of mTHPC and pegylated mTHPC 1065
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Table 3 Tissue concentration measurements for mTHPCa and pegylated
mTHPCb in the tumour and normal tissues (ng/g tissue, mean ± 1 SD)
mTHPC Pegylated mTHPC
Mesothelioma 0.07 ± 0.06 0.13 ± 0.08
Adenocarcinoma 0.07 ± 0.007 0.19 ± 0.08
Squamous cell carcinoma 0.08 ± 0.02 0.01 ± 0.002
Heart 0.05 ± 0.03 0.41 ± 0.13
Lung 0.07 ± 0.01 0.10 ± 0.01
Liver 0.05 ± 0.01 0.15 ± 0.02
Spleen 0.07 ± 0.01 0.16 ± 0.05
Kidney 0.11 ± 0.02 0.06 ± 0.01
Gut 0.18 ± 0.07 0.16 ± 0.05
Skin 0.07 ± 0.02 0.07 ± 0.03
Muscle 0.01 ± 0.003 0.02 ± 0.01
aAssessment 4 days after i.p. injection of 0.1 mg/kg mTHPC. bAssessment
4 days after i.p. injection of pegylated mTHPC equimolar dosed to 0.1 mg/kg
mTHPC.previous study with mTHPC showed that photodynamic activity
does not correlate with the absolute concentration of the sensitizer
in tissue measured by HPLC and does not help to predict the photo-
sensitizing effect (Ris et al, 1993a). This appears to be a common
finding for other sensitizers (Gibson et al, 1994). Caution is there-
fore indicated in predicting the photosensitizing properties of a
compound according to its tissue uptake as measured by HPLC.
Pegylated mTHPC resulted in extensive photosensitized necrosis in
squamous cell carcinoma xenografts at a drug-light interval of 4
days despite a low tumour uptake at this time point.
The efficacy and tumour selectivity of PDT using mTHPC is
highly dependent on modulations of the drug-light conditions (Ris et
al, 1993b). mTHPC (0.1 mg/kg) and 20 J/cm2 gave little damage to
normal tissues at drug-light intervals ranging from 2 to 4 days but at
an interval of 1 day extensive necrosis in skin and muscle occurred.
With the same treatment conditions marked necrosis in malignant
mesothelioma was observed without differences between the various
drug-light intervals assessed (1—4 days). The same drug-light condi-
tions at an interval of 4 days led also to photosensitized necrosis in
squamous cell carcinoma and adenocarcinoma. However, necrosis in
adenocarcinoma was significantly larger than in mesothelioma and
squamous cell carcinoma. This difference in the extent of photosensi-
tized tumour necrosis could not be attributed to a difference in
tumour uptake of mTHPC. Since the experimental setting was iden-
tical for the three tumour types, we speculate that this phenomenon
might be related to a difference in histology and vascular architecture
of the xenografts leading to differences in vascular-related photo-
sensitizing effects and direct tumour cell injury (Peng et al, 1995).
Whereas adenocarcinoma xenografts revealed histologically a deli-
cate tumour stroma with numerous small capillary vessels, the
xenografts of malignant mesothelioma and squamous cell carcinoma
were poor in stroma and blood vessels.
In contrast, the photosensitizing effect of pegylated mTHPC was
much less dependent on the histology of the tumours and the drug-
light conditions applied. A further improvement of PDT comparing
efficacy and tumour selectivity was obtained in this model by use of
pegylated mTHPC instead of mTHPC. No obvious changes were
observed in normal tissues with an equivalent dose of pegylated
mTHPC and 20 J/cm2 at any drug-light interval assessed, remark-
ably not even at a drug-light interval of 1 day where extensive
normal tissue necrosis is seen with mTHPC. At the same time a
significant increase in the extent of necrosis was found in malignant
mesothelioma xenografts compared to that obtained with mTHPC at
identical drug-light conditions but longer drug-light intervals with
best results being observed at 4 days. Pegylated mTHPC also gave a
uniform necrosis for all xenografts without significant difference
between malignant mesothelioma, squamous cell carcinoma and
adenocarcinoma, with larger necrosis in malignant mesothelioma
and squamous cell carcinoma being observed than with mTHPC.
Our results indicated that pegylated mTHPC revealed enhanced
photosensitizing properties than the non-pegylated compound,
which might be related to enhanced targeting of this sensitizer on
the tumour, and possibly within a specific site at the tumour cell.
Tissue concentrations measured by HPLC were of little use to
predict the photosensitizing effects of both, mTHPC and pegylated
mTHPC in this model.
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